Thank you for submitting your manuscript for consideration by the EMBO Journal. It has now been seen by two referees whose comments are shown below.
As you can see below, the referees find the analysis interesting. However, they also both find that further experiments are needed to consider publication here. Should you be able to address the concerns raised and extend some of their key findings to a more endogenous system then I would like to invite you to submit a revised version. I should add that it is EMBO Journal policy to allow only a single major round of revision and that it is therefore important to address the raised concerns at this stage.
------------------------------------------------REFEREE REPORTS:
Referee #1:
This manuscript identifies RNF34 as a negative regulator of MAVS function in inducing type I interferon. The authors clearly demonstrate that RNF34 ubiquitinates MAVS during signaling using K27 and K29 ubiquitin linkages. They also map the amino acids on MAVS that become ubiquitinated and show that leads to MAVS interaction with NDP52, an autophagy adapter protein that binds to ubiquitin. They then suggest that this ubiquitination of MAVS leads to its autophagic degradation via mitophagy. They propose that RNF34 targeting of MAVS occurs on MAVS aggregates ,which are known to form down inducing of the RLR-MAVS signaling pathway, and suggest that RNF34 may be a another protein (similar to the ubiquitin ligase MARCH5) that resolves MAVS aggregates by inducing their mitophagy. While simply the identification of another negative regulator of MAVS signaling is not all that novel, this work really nicely shows the mechanism of how RNF34 acts on MAVS, and this provides new, important insights into the regulation of this antiviral signaling pathway. The conclusions of the work are generally wellsupported by the presented data; however, the conclusions that RNF34 is targeting MAVS aggregates and the links to mitophagy are not as strong, and I don't think they add much to the story. I have several comments for the authors to address:
Major comments:
1. The conclusion that RNF34 acts on MAVS aggregates is currently over-stated because the authors do not uncouple aggregation from MAVS signaling in this manuscript. Maybe RNF34 only interacts with signaling-active MAVS and it has nothing to do with aggregation? The authors should confirm in their own hands that the MAVS R64/65A mutant does not aggregate in order to prove that RNF34 only interacts with aggregated MAVS. Does this mutant stimulate signaling to IFN-beta? How do the authors know that the interaction and ubiquitination in Fig. 3 is specific to aggregation defects vs signaling defects? Indeed Fig. 4F shows that this mutant doesn't signal. The authors could perhaps uncouple these points by measuring the kinetics of MAVS aggregation and induction of p-IRF3 to mark signaling and then in the same course determine the time points at which RNF34 first interacts with and ubiquitinates MAVS. 2. Related, the data shown does not support the conclusion that RNF34 recognizes MAVS aggregates. It does seem to prevent their formation. (Fig. 4) These experiments are not essential and the authors could remove the claims that RNF34 only interacts with / acts on aggregated MAVS and that would not lessen the impact of this work 3. In the EV Figure 2 , the authors claim in the text that RNF34 affects MAVS protein levels, which it appears to do in C but not in panel A. What explains these differences? 4. The data from the PLA assay in Fig. 2F needs quantification of the spots from multiple cells in order to conclude that the number of spots increases depending over time and to show how representative these images actually are. 5. In the main text, the authors should explain the scientific rationale for the treatment with NH4CL and 3-MA (related to Figure 4 ). It would be important to show if this treatment alters VSV protein levels in this experiment to confirm that it is not just loss of VSV infection that is restoring MAVS protein levels (Fig. 4B) . Also, the authors show no evidence that VSV infection induces autophagythey need to show this to conclude that the changes in MAVS levels are due to VSV-induction of autophagy (Fig. 4C ). 6. The figure legends should state what the bars (mean or median?) and error bars (SD or SEM?) on the graph represent (from how many replicates?), as well as define the statistical analysis used and what the stars represent. How many times have the western blots / IPs been repeated? 7. The data in Fig. 5E that the MAVS 4KR mutant is not degraded by RNF34 over-expression is not quite convincing. Quantification from 3 biological replicates and showing a representative blot would be more convincing. 8. The authors claim in Fig. 6J that loss of NDP52 increases the stability of MAVS upon VSV infection, but the authors can't claim stability without doing a cyclohexamide/pulse chase experiment. They should either do that or adjust the statement to say MAVS protein levels (instead of stability). 9. How do the authors know that the loss of mitochondria during VSV infection (as measured by loss of TOM20 and HSP60) is not simply due to VSV-induction of cell death and not actually mitophagy? Is this innate immune related or simply cell death related? Indeed, the mitochondria in Fig. S7A appear to be from a dying cell (and these look very different than the MAVS staining in Fig. 7C ). It seems like the claim of viral (VSV)-induced mitophagy for clearing MAVS aggregates is over-stated as there are no controls to show that this is not an artefact of cell death or good proof that this is indeed mitophagy and not just cell death.
Minor comments:
1. In the introduction, the authors state that "several E3 ligases...TRIM25...have been shown to facilitate degradation of MAVS." However, the reference they provide, Gack 2007, is about how TRIM25 ubiquitinates RIG-I to activate it and not about MAVS. 2. The bright field cells in Fig. 1I are difficult to see. I would suggest adjusting the brightness and/or contrast. 3. Sometimes the authors refer to supplemental figures as EV1D and sometimes Fig S1F. 4. In the text, the authors refer to EV4D and E, but I think they mean C and D?
Referee #2:
In the manuscript "RNF34 functions in immunity and selective mitophagy by targeting MAVS aggregates for autophagic degradation" by He et al, the authors report that the cytosolic E3 ubiquitin ligase RNF34 targets MAVS for NDP52-directed selective autophagic degradation to prevent the activation of RLR-mediated type I interferon signaling. There are several concerns (some listed below) that I have with this study. Most of these concerns are associated with the novelty of the paper that autophagic degradation of MAVS has been reported before, so the authors should perform more detailed experiments and in vivo study. However, the experiments are mainly performed in cell lines (especially 293T cells) and the main conclusions are obtained from overexpression systems. The authors should validate their data in primary cells, such as PBMCs, and perform most of their experiments in endogenous system in THP-1 cells or PBMCs, but not 293T cells.
Some results are not convincing and this manuscript falls short from fully clarifying the physiological role of RNF34 in MAVS degradation and IFN signaling. Specific comments are listed below. Major comments: 1. The data presented in Figure 1A -C indicate that RNF34 suppresses the activation of type I IFN signaling induced by MAVS, RIG-I (N) and intracellular poly (I:C). However, whether RNF34 affects the activation of type I IFN signaling mediated by cGAS/STING, and the potential role of RNF34 in other innate immune signaling pathways, such as NF-κB signaling remains unknown. 2. As the fold change of ISRE-luc assay activated by TBK1 is quite weak in this research and in fact, overexpression of STING only is not sufficient to active ISRE-luc reporter, the data presented in Figure 2A are not reasonable. 3. The data presented in Figure 3A are not consistent with Figure 3C and 3D. RNF34 may promote the degradation of MAVS in an enzyme activity dependent manner, so the protein abundance of Flag-MAVS in lane 1 will be much lower than that of in lane 2 and lane 3 of lysate. 4. mRNAs encoding human MAVS produce two proteins via alternative translation: MAVS and miniMAVS. These proteins have distinct functions. The authors demonstrate that RNF34 forms a complex with MAVS, but they do not indicate which form of MAVS they are detecting. Does RNF34 form a complex with miniMAVS and promote the autophagic degradation of miniMAVS? What is the significance of these interactions? 5. Why the western blotting images of Flag-MAVS have two bands in Figure 3 and Figure 4 ? The two neighboring bands may not be the full-length MAVS and miniMAVS. Does this caused by the contamination or the mutation of the plasmid the authors used? 6. In Figure 4E , the degradation of MAVS mediated by RNF34 can be largely abolished by 3MA and NH4Cl treatment. Whether RNF34 itself can go through autophagic degradation? Is seems that NH4Cl treatment leads to the accumulation of RNF34 in the left image of Figure 4E , but the result is not consistent with the right part of Figure 4E . The authors should check the degradation of endogenous MAVS and RNF34 and investigate whether RNF34 is an autophagy substrate. 7. The description of the manuscript is not consistent with Figure EV4A , as RNF34 can still promotes the degradation of MAVS in ATG7 depletion cells. To further confirm that RNF34 contributes to the autophagic degradation of MAVS, the authors should examine the role of RNF34 in several other autophagy-related gene deficiency cells, such as ULK1, Beclin-1, ATG5-ATG12 depletion cells. In Figure EV4C , the authors knockdown the expression of BST2/Tetherin and detect the role of RNF34. In fact, BST2 is an inducible interferon stimulated gene (ISG), and the protein expression of BST2 can be hardly detected without virus infection, thus it is not right to discover the exact role of RNF34 in BST2 null cells like that. The authors should use virus to infect the cells and used Western Blot to check the expression of BST2. 8. In Figure 5 , the authors show that Lys 311 of MAVS can be ubiquitinated by RNF34 with K27-linkage to go through mitophagy degradation, however, Liu et al. (Nature Immunology, 2017) indicated TRIM31 catalyzes K63-linked polyubiquitination of Lys 311 on MAVS and promotes the prion-like aggregates of MAVS to activate the type I IFN signaling pathway. This is confusing for us to known the physiological role of Lys 311 on MVAS in vivo. Whether RNF34 initiates the K63-K27 ubiquitination transition of MAVS on Lys 311? The authors should address this concern and reveal the detail mechanism underlying the ubiquitination modification of MAVS. 9. Finally, it is popular known that mouse NDP52 has no the ubiquitin binding domain, it would a very good proof of concept if the authors test RNF34/NDP52 axis-dependent MAVS degradation in mouse cell lines. If this pathway does not hold true in mouse cells then the authors should place human NDP52 in mice to restore the autophagic degradation of MAVS.
Minor comments: 1. The authors should detect the expression of endogenous RNF34 under virus infection. 2. The authors have better devote at least some space in introduction and discussion to present previous reports about MAVS ubiquitination modification revealed by other researchers, and place more emphasis on the difference between their work with other studies. 3. In the Materials and Methods part for western blotting and immunoprecipitation, several antibodies have the error citations for product codes. 4. Since the autophagic degradation of MAVS by NDP52 has been reported, it is better to mention and discuss it with the new findings in the Introduction and Discussion part. Response to reviewers point to point: Major comments: 1. The conclusion that RNF34 acts on MAVS aggregates is currently over-stated because the authors do not uncouple aggregation from MAVS signaling in this manuscript. Maybe RNF34 only interacts with signaling-active MAVS and it has nothing to do with aggregation? The authors should confirm in their own hands that the MAVS R64/65A mutant does not aggregate in order to prove that RNF34 only interacts with aggregated MAVS. Does this mutant stimulate signaling to IFN-beta? How do the authors know that the interaction and ubiquitination in Fig. 3 is specific to aggregation defects vs signaling defects? Indeed Fig. 4F shows that this mutant doesn't signal. The authors could perhaps uncouple these points by measuring the kinetics of MAVS aggregation and induction of p-IRF3 to mark signaling and then in the same course determine the time points at which RNF34 first interacts with and ubiquitinates MAVS. EV Figure 2F -G showing the ability of MAVS R64/65A mutant to form aggregate and stimulate IFN-β were added in the revised version as below. In order to uncouple aggregation defects vs signaling defects, we added IFN-α into the immunoprecipitation system. As we can see, the ability of MAVS-R64/65A mutant to interact with RNF34 was also dramatically reduced even in the presence of IFN-α ( Fig 2J) .
2. Related, the data shown does not support the conclusion that RNF34 recognizes MAVS aggregates. It does seem to prevent their formation. (Fig. 4 ) These experiments are not essential and the authors could remove the claims that RNF34 only interacts with / acts on aggregated MAVS and that would not lessen the impact of this work.
In the revised version, to avoid overstatement, we removed the claims that RNF34 only interacts and acts on aggregated MAVS by emphasizing its effect on K27-linked ubiquitination and autophagic degradation of MAVS aggregates. We found that overexpression of TRIM31 or RNF34 markedly promoted the K63-and K27-linked ubiquitination of MAVS, respectively ( Fig 4C) . Notably, the K63-linked ubiquitination of MAVS catalyzed by TRIM31 was dramatically reduced by RNF34 overexpression, whereas the K27-linked polyubiquitination of MAVS induced by RNF34 was unaffected by TRIM31. Moreover, RNF34 overexpression decreased the K63-linked polyubiquitination of MAVS, but had little effect on MAVS K311R mutant ( Fig 4C) . We then analyzed the effects of RNF34 and TRIM31 on the pattern of endogenous MAVS polyubiquitination in VSV-infected THP-1 macrophages. Interestingly, VSV infection enhanced the K63-and K27-linked ubiquitination of MAVS at 6 hpi. The levels of K63-linked ubiquitinated MAVS were significantly reduced by TRIM31 silencing, while silencing of RNF34 significantly decreased the levels of K27-linked ubiquitinated MAVS. Specifically, the levels of K63-linked ubiquitinated MAVS was further accumulated upon RNF34 silencing ( Fig 4D) . To directly address the function of RNF34-induced K63-K27 ubiquitination transition on the degradation of MAVS aggregates, we next transfected MAVS together with RNF34 and/or TRIM31. As shown in Fig 5K, RNF34 overexpression decreased the levels of MAVS aggregates induced by TRIM31. Thus, RNF34 promotes the autophagic degradation of MAVS aggregates upon RIG-I stimulation. Nevertheless, it is easy to delete the data about MAVS R64/65A part if needed.
3. In the EV Figure 2 , the authors claim in the text that RNF34 affects MAVS protein levels, which it appears to do in C but not in panel A. What explains these differences? EV Figure 2A were cropped using Photoshop software (Adobe) and band density was analyzed using Image-Quant software (Amersham). As we can see, RNF34 downregulated MAVS protein level, but to a lesser extent than that in Figure 2C . The difference may be due to the amount of the transfected RNF34.
4. The data from the PLA assay in Fig. 2F needs quantification of the spots from multiple cells in order to conclude that the number of spots increases depending over time and to show how representative these images actually are. 100 cells in Figure 2F were counted and quantification of PLA signals per cell was shown in EV Figure 2E as below:
5. In the main text, the authors should explain the scientific rationale for the treatment with NH4CL and 3-MA (related to Figure 4 ). It would be important to show if this treatment alters VSV protein levels in this experiment to confirm that it is not just loss of VSV infection that is restoring MAVS protein levels (Fig. 4B) . Also, the authors show no evidence that VSV infection induces autophagythey need to show this to conclude that the changes in MAVS levels are due to VSV-induction of autophagy (Fig. 4C ).
The scientific rationale for the treatment with NH4CL,3-MA and MG132 was added into the results part marked in red in the revised version: As the K27/K29 ubiquitin linkage correlates with the autophagic degradation of proteins, we next investigated the biological consequences of RNF34-mediated ubiquitination of MAVS. Therefore, the autophagy inhibitor 3-methyladenine (3-MA), autolysosome inhibitor NH4Cl or proteasome inhibitor MG132 was used. VSV-G and LC3 antibody was used. New Figure 5B showed that at 12 hpi, the expression of VSV-G was similar in control and NH4Cl-treated group, however, MAVS degradation was obvious only in control group, supporting the role of autophage in regulating the degradation of MAVS. EV Figure 5A showed that VSV infection induces autophagy indicated by LC3 expression. Cell-based studies were performed at least three times independently with comparable results. The luciferase and ELISA data are presented as the mean ± SEM. Two-tailed Student's t-test was used for statistical analysis: *, P < 0.05; **, P < 0.01; ***, P < 0.001. This was added to the figure legends marked in red in the revised version. 7. The data in Fig. 5E that the MAVS 4KR mutant is not degraded by RNF34 over-expression is not quite convincing. Quantification from 3 biological replicates and showing a representative blot would be more convincing. A representative blot from 3 independent experiments was chosen as Figure 5F as below:
The authors claim in Fig. 6J that loss of NDP52 increases the stability of MAVS upon VSV infection, but the authors can't claim stability without doing a cyclohexamide/pulse chase experiment. They should either do that or adjust the statement to say MAVS protein levels (instead of stability). We adjusted the statement from stability to MAVS protein level. 9. How do the authors know that the loss of mitochondria during VSV infection (as measured by loss of TOM20 and HSP60) is not simply due to VSV-induction of cell death and not actually mitophagy? Is this innate immune related or simply cell death related? Indeed, the mitochondria in Fig. S7A appear to be from a dying cell (and these look very different than the MAVS staining in Fig. 7C ). It seems like the claim of viral (VSV)-induced mitophagy for clearing MAVS aggregates is over-stated as there are no controls to show that this is not an artefact of cell death or good proof that this is indeed mitophagy and not just cell death.
To exclude the possible effect of VSV-induced cell death on the loss of mitochondria from VSVinduced mitophagy, we treated cells with Z-VAD-FMK, a pan-caspase inhibitor that can block virus-induced cell death. Significant mitophagy defect was also observed in siRNF34-1 cells in response to VSV infection in the presence of Z-VAD (EV Fig 7A-B) . Furthermore, we used Keima, a pH-sensitive fluorescent protein targeted to the mitochondria, to measure mitophagy flux in cells.
Compared with control cells, RNF34 overexpression stimulated Keima shifting from 458 nm to 543 nm, indicating the increased mitochondria entering to the acidic environment of the lysosome in response to VSV infection (Fig 7F) .
Minor comments: 1. In the introduction, the authors state that "several E3 ligases...TRIM25...have been shown to facilitate degradation of MAVS." However, the reference they provide, Gack 2007, is about how TRIM25 ubiquitinates RIG-I to activate it and not about MAVS. We tried to present the novelty of the paper in two ways in the revised version: 1. RNF34 regulates regulates the innate immune response and mitochondrial homeostasis upon viral infection. This was validated in endogenous system in PBMCs and THP-1 cells in the revised version as below: To further delineate the physiological role of RNF34, THP-1 cells and human peripheral blood mononuclear cells (PBMCs) were used. RNF34 deficiency dramatically increased TBK1 and IRF3 phosphorylation in response to VSV infection in both cell lines ( Figs 1G and EV1K ). RNF34 knockdown decreased VSV-triggered IFN-β production at both the mRNA and protein levels ( Fig  1H-I ). In addition, RNF34 knockdown significantly decreased the expression of IL8, ISG54 and ISG56 upon VSV infection compared with cells transfected with the control scramble siRNA ( Fig  1J) . As expected, lower VSV-G expression was observed in siRNF34-transfected THP-1 cells ( Fig  1G) . Taken together, these results suggested that RNF34 is a negative regulator of RLR-mediated type I IFN signaling. These were added into the results part marked in red. Fig 1G,H,I ,J and Fig  EV1K were added to the revised version as below:
2. Mechanistically, RNF34 binds to full length MAVS in the mitochondrial compartment and promotes its K63 to K27 polyubiquitination transition primarily at Lys 311. The K27-linked polyubiquitination MAVS is recognized by the cargo receptor NDP52 and results in the recruitment of damaged mitochondria with enriched MAVS aggregates to the vacuole for autophagic degradation. Data including the effect of RNF34 on the levels of MAVS, mMAVS, R64/65A, the K63-K27-linked ubiquitination, and aggregation were added in the revised version. By adding these data, we revealed that one single site catalyzed by different E3 ligases with different ubiquitination modes can deliberately regulate the protein fate of MAVS. In addition, RNF34 only targeted fulllength MAVS for degradation without affecting the expression of mMAVS. Thus, our results suggest a unique mechanism by which the expression of full-length MAVS decreases over time, while the expression of the mMAVS remains constant during an RNA virus infection. All these diverse regulatory mechanisms for MAVS reveal a spatial and temporal regulation network to orchestrate antiviral immunity. Please see the detailed data in the specific comments.
Major comments: 1. The data presented in Figure 1A -C indicate that RNF34 suppresses the activation of type I IFN signaling induced by MAVS, RIG-I (N) and intracellular poly (I:C). However, whether RNF34 affects the activation of type I IFN signaling mediated by cGAS/STING, and the potential role of RNF34 in other innate immune signaling pathways, such as NF-κB signaling remains unknown. The potential effect of RNF34 on IFN-β activation mediated by cGAS/STING and NF-κB signaling induced by RIG-I (N) was analyzed. EV Figures 1G,I ,J were added into the revised version as below. As we can see, RNF34 is not involved in the regulation of cGAS/STING or poly (dA:dT)-induced IFN-I signaling (Fig EV1G,I ). Repressions of poly (I:C)-induced activation of NF-κB reporter by RNF34 were also observed ( Fig EV1J) .
2. As the fold change of ISRE-luc assay activated by TBK1 is quite weak in this research and in fact, overexpression of STING only is not sufficient to active ISRE-luc reporter, the data presented in Figure 2A are not reasonable. Activation of ISRE-Luc reporter by overexpression of STING in 293T cells was reported in several published paper including Glen N. Barber's Nature paper in 2008. They found that overexpression of STING in 293T cells robustly induce the expression of the NF-kB responsive promoter and ISRE promoters (c-d). Activation of ISRE-luc by TBK1 and STING was relatively weak in our manuscript may be due to their low expression levels (Fig 2A and Fig EV 2A) . We also repeated several times with comparable results in our hand by using this system. As this is not a critical data influencing our conclusion, surely we can change different cell lines or reporter promoter to replace this one if needed.
3. The data presented in Figure 3A are not consistent with Figure 3C and 3D. RNF34 may promote the degradation of MAVS in an enzyme activity dependent manner, so the protein abundance of Flag-MAVS in lane 1 will be much lower than that of in lane 2 and lane 3 of lysate. A representative blot from 3 independent experiments was used and added as Figure 3A in the revised version as below:
4. mRNAs encoding human MAVS produce two proteins via alternative translation: MAVS and miniMAVS. These proteins have distinct functions. The authors demonstrate that RNF34 forms a complex with MAVS, but they do not indicate which form of MAVS they are detecting. Does RNF34 form a complex with miniMAVS and promote the autophagic degradation of miniMAVS? What is the significance of these interactions? The MAVS mRNA is bicistronic coding for MAVS and a truncated mMAVS protein that differ by 142 amino acid residues. mMAVS restricts MAVS-induced antiviral responses without being a component of MAVS aggregates or regulating the formation of MAVS aggregate(albeit controversial). To determine whether RNF34 interacts with mMAVS isoform, we generated MAVS truncation mutant (Fig EV2H) , and found that RNF34 failed to bind mMAVS (Fig 2K) . In consistence with the binding data, RNF34 failed to downregulate mMAVS expression (Fig 5E) .
The significant of these interactions was clarified in the introduction and discussion part marked in red in the revised version: Introduction part: At the post-transcriptional level, the translation of MAVS is initiated at two different translation start sites and results in expression of a shorter isoform of MAVS composed of 398 amino acids that lacks the CARD domain (mMAVS). Researchers have proposed that mMAVS functions as a negative regulator of the antiviral response. Discussion part: RNF34 does not associate with mMAVS and downregulate its expression, further highlighting the negative role of RNF34 in MAVS-mediated type I IFN signaling. Figure 3 and Figure 4 ? The two neighboring bands may not be the full-length MAVS and miniMAVS. Does this caused by the contamination or the mutation of the plasmid the authors used? One of the two neighboring bands are definitely not miniMAVS, contamination and mutation was excluded by single clone picking and sequencing. We proposed that the activation of TBK1 kinase activity by Flag-MAVS transfection will lead to the phosphorylation modification of MAVS. By using TBK1 kinase inhibitor BX795, the slower moving band gradually became invisible.
Why the western blotting images of Flag-MAVS have two bands in
Furthermore, some of researchers show one clean band by Flag-MAVS overexpression, while others show multiple bands.
6. In Figure 4E , the degradation of MAVS mediated by RNF34 can be largely abolished by 3MA and NH4Cl treatment. Whether RNF34 itself can go through autophagic degradation? Is seems that NH4Cl treatment leads to the accumulation of RNF34 in the left image of Figure 4E , but the result is not consistent with the right part of Figure 4E . The authors should check the degradation of endogenous MAVS and RNF34 and investigate whether RNF34 is an autophagy substrate. The protein levels of endogenous MAVS and RNF34 was analyzed and new EV Figure 5A was added as below. Results indicated that RNF34 is not an autophagy substrate. We bought nearly all the commercial available antibodies, none of them works well. Sorry we cannot provide WB with better quality at present.
7. The description of the manuscript is not consistent with Figure EV4A , as RNF34 can still promotes the degradation of MAVS in ATG7 depletion cells. To further confirm that RNF34 contributes to the autophagic degradation of MAVS, the authors should examine the role of RNF34 in several other autophagy-related gene deficiency cells, such as ULK1, Beclin-1, ATG5-ATG12 depletion cells. In Figure EV4C , the authors knockdown the expression of BST2/Tetherin and detect the role of RNF34. In fact, BST2 is an inducible interferon stimulated gene (ISG), and the protein expression of BST2 can be hardly detected without virus infection, thus it is not right to discover the exact role of RNF34 in BST2 null cells like that. The authors should use virus to infect the cells and used Western Blot to check the expression of BST2. The knockdown efficacy of ATG7 was about 70%, we suggested that ATG7 knockdown partially blocked RNF34-induced MAVS degradation (Fig EV5B-C) . In addition to ATG7, we also examined the role of ATG5 in RNF34-induced MAVS degradation (Fig EV5B,D) . Flag-MAVS overexpression can induce IFN-I activation and BST2 induction, still, we repeated this experiments by using VSV infection and Figure EV5F was added.
8. In Figure 5 , the authors show that (Fig 4C) . Notably, the K63-linked ubiquitination of MAVS catalyzed by TRIM31 was dramatically reduced by RNF34 overexpression, whereas the K27-linked polyubiquitination of MAVS induced by RNF34 was unaffected by TRIM31. Moreover, RNF34 overexpression decreased the K63-linked polyubiquitination of MAVS, but had little effect on MAVS K311R mutant (Fig 4C) . We then analyzed the effects of RNF34 and TRIM31 on the pattern of endogenous MAVS polyubiquitination in VSV-infected THP-1 macrophages. Interestingly, VSV infection enhanced the K63-and K27-linked ubiquitination of MAVS at 6 hpi. The levels of K63-linked ubiquitinated MAVS were significantly reduced by TRIM31 silencing, while silencing of RNF34 significantly decreased the levels of K27-linked ubiquitinated MAVS. Specifically, the levels of K63-linked ubiquitinated MAVS was further accumulated upon RNF34 silencing (Fig 4D) .
Results of co-immunoprecipitation analysis revealed endogenous TRIM31, RNF34 and MAVS formed a complex in PBMCs after infection with VSV ( Fig 4E) . Together, these data indicated that RNF34 initiates the K63 to K27-linked polyubiquitination transition on MAVS primarily at Lys 311.
To directly address the function of RNF34-induced K63-K27 ubiquitination transition on the degradation of MAVS aggregates, we next transfected MAVS together with RNF34 and/or TRIM31. As shown in Fig 5K, RNF34 overexpression decreased the levels of MAVS aggregates induced by TRIM31. Thus, RNF34 promotes the autophagic degradation of MAVS aggregates upon RIG-I stimulation.
9. Finally, it is popular known that mouse NDP52 has no the ubiquitin binding domain, it would a very good proof of concept if the authors test RNF34/NDP52 axis-dependent MAVS degradation in mouse cell lines. If this pathway does not hold true in mouse cells then the authors should place human NDP52 in mice to restore the autophagic degradation of MAVS. We added this to the results part: RNF34 failed to degrade MAVS in MEFs expressing mouse NDP52 lacking the ubiquitin binding domain. The reintroduction of human NDP52 restored the RNF34-induced degradation of MAVS (Fig EV6E) .
Minor comments: 1. The authors should detect the expression of endogenous RNF34 under virus infection.
Immunofluorescence results showed that low levels of RNF34 colocalized with MAVS even in the absence of VSV infection. VSV infection increased colocalization of RNF34 with MAVS in the mitochondrial compartment (Fig 2F and Fig EV2D) . Notably, the protein levels of RNF34 were significantly upregulated (from 6 hpi) following VSV infection in THP-1 cells (Fig 2G) .
2. The authors have better devote at least some space in introduction and discussion to present previous reports about MAVS ubiquitination modification revealed by other researchers, and place more emphasis on the difference between their work with other studies. Thank you for submitting your revised manuscript to The EMBO Journal. Your study has now been seen by the two referees and their comments are provided below. As you can see, the referees appreciate the introduced changes and support publication here. The referees have a few remaining concerns that I would like to ask you to address in a final revision.
The experiments suggested by referee #2 should be feasible yes? If not let me know
When you submit the revised version would you also take care of the following points:
The authors had previously suggested that RNF34 acts on MAVS aggregates to promote signaling. For this point, they showed that RNF34 does not interact with a MAVS mutant (R64/65A) that doesn't aggregate and does not signal. However, it's unclear if the failure of RNF34 to interact with this MAVS mutant is due to its inability to signal or its inability to aggregate. I had previously suggested that examining the RLR-signaling (e.g. VSV) induced kinetics of (1) MAVS aggregation, with (2) induction of p-IRF3 to mark signaling, and (3) MAVS-RNF34 interaction could reveal which comes first, second, and third. Instead the authors did an experiment, shown in Figure 2I of the manuscript, labeled as 2J in the response to reviewers, to look at MAVS-RNF34 interaction in the presence of IFN-alpha. The logic of doing this new experiment, or how it addressed the concern that I had expressed, is unclear to me, as MAVS signaling is not regulated by IFN-alpha. The goal should be to uncouple aggregation from RLR-signaling, not IFN signaling. That being said, as the authors have de-emphasized some of the MAVS aggregates aspects, I would suggest simply removing this data as the logic behind doing this experiment doesn't make sense.
The quantification for the PLA shown in Fig. 2H , presented at EV Figure 2E , is important, and should be in the main panel of figures, not in the supplemental.
Besides these two points, the authors have addressed all of my other previous concerns.
The paper has been significantly improved in this round of revision. So I recommended accepation of this paper after addressing the following concerns. There are two concerns about the results mainly for Fig 5-6: (1) All the IP experiments in Fig 5-6 (RNF34, NDP52, MAVS, etc) are based on overexpression system, it is better to replace them (at least for some ciritical experiments such as Fig 6F,6K ) in endogenous system just like they present in Fig 4E. (2) In most of the degradation experiments, the authors overexpressed both MAVS and RNF34, it is better to replace them with endogenous blots (at least one protein should be detected by endogenous antibodies, for exmple in Fig 5G, it is no need to overexpress MAVS, it is better to directly detect endogenous MAVS). A point-by-point response to the referees' comments with a detailed description of the changes made.
The authors had previously suggested that RNF34 acts on MAVS aggregates to promote signaling. For this point, they showed that RNF34 does not interact with a MAVS mutant (R64/65A) that doesn't aggregate and does not signal. However, it's unclear if the failure of RNF34 to interact with this MAVS mutant is due to its inability to signal or its inability to aggregate. I had previously suggested that examining the RLR-signaling (e.g. VSV) induced kinetics of (1) MAVS aggregation, with (2) induction of p-IRF3 to mark signaling, and (3) MAVS-RNF34 interaction could reveal which comes first, second, and third. Instead the authors did an experiment, shown in Figure 2I of the manuscript, labeled as 2J in the response to reviewers, to look at MAVS-RNF34 interaction in the presence of IFN-alpha. The logic of doing this new experiment, or how it addressed the concern that I had expressed, is unclear to me, as MAVS signaling is not regulated by IFN-alpha. The goal should be to uncouple aggregation from RLR-signaling, not IFN signaling. That being said, as the authors have de-emphasized some of the MAVS aggregates aspects, I would suggest simply removing this data as the logic behind doing this experiment doesn't make sense. We removed the Figures including Figure 2I , 3B, 5C, 5D, EV Figure 2F -G and EV Figure 5E in the revised version and deleted all the statements about "RNF34 acts on MAVS aggregates to promote signaling". The quantification for the PLA shown in Fig. 2H , presented at EV Figure 2E , is important, and should be in the main panel of figures, not in the supplemental. The quantification for the PLA in EV Figure 2E was presented as Figure 2I in the revised version. The changes in figure legends and results part were marked in red.
Besides these two points, the authors have addressed all of my other previous concerns. Referee #2: The paper has been significantly improved in this round of revision. So I recommended accepation of this paper after addressing the following concerns. There are two concerns about the results mainly for Fig 5-6: (1) All the IP experiments in Fig 5-6 (RNF34, NDP52, MAVS, etc) are based on overexpression system, it is better to replace them (at least for some ciritical experiments such as Fig 6F,6K ) in endogenous system just like they present in Fig 4E. New Figures 6F, 6K in endogenous system was added in the revised version as requested.
(2) In most of the degradation experiments, the authors overexpressed both MAVS and RNF34, it is better to replace them with endogenous blots (at least one protein should be detected by endogenous antibodies, for exmple in Fig 5G, it is no need to overexpress MAVS, it is better to directly detect endogenous MAVS). New Figures 5E using endogenous MAVS to analysis the impact of RNF34 on MAVS level was in the revised version as requested. Thank you for submitting your revised version to The EMBO Journal. I have now had a chance to take a look at it and looks good. I am therefore very pleased to accept the manuscript for publication here. Any descriptions too long for the figure legend should be included in the methods section and/or with the source data.
In the pink boxes below, please ensure that the answers to the following questions are reported in the manuscript itself. Every question should be answered. If the question is not relevant to your research, please write NA (non applicable). We encourage you to include a specific subsection in the methods section for statistics, reagents, animal models and human subjects.
definitions of statistical methods and measures:
a description of the sample collection allowing the reader to understand whether the samples represent technical or biological replicates (including how many animals, litters, cultures, etc.).
Please fill out these boxes # (Do not worry if you cannot see all your text once you press return) a specification of the experimental system investigated (eg cell line, species name).
B--Statistics and general methods
the assay(s) and method(s) used to carry out the reported observations and measurements an explicit mention of the biological and chemical entity(ies) that are being measured. an explicit mention of the biological and chemical entity(ies) that are altered/varied/perturbed in a controlled manner.
Data
the data were obtained and processed according to the field's best practice and are presented to reflect the results of the experiments in an accurate and unbiased manner. figure panels include only data points, measurements or observations that can be compared to each other in a scientifically meaningful way. graphs include clearly labeled error bars for independent experiments and sample sizes. Unless justified, error bars should not be shown for technical replicates. if n< 5, the individual data points from each experiment should be plotted and any statistical test employed should be justified the exact sample size (n) for each experimental group/condition, given as a number, not a range;
Each figure caption should contain the following information, for each panel where they are relevant:
Captions
The data shown in figures should satisfy the following conditions:
Source Data should be included to report the data underlying graphs. Please follow the guidelines set out in the author ship guidelines on Data Presentation.
YOU MUST COMPLETE ALL CELLS WITH A PINK BACKGROUND #
Sample sizes were chosen based on prior experiments and general standards employed in the field.The report of significant or nonsignificant is based on at least 3 biological replicates.
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NA.
Yes.The stastical measures used for each experiments are indicated in the figure legends and also in the "Materials and Methods" under"Statistical analyses".
Yes.The paired Student's t--test were used to assess the normality of the data.
Yes.Data are represented as Mean ± SEM as stated.
Yes.
